about
Environmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer PreventionSmall molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cellsCTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions.Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma.Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells.Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer.Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation.CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model.Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Status of Anaplastic Lymphoma Kinase (ALK) in malignant mesothelioma.CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence.MicroRNA in Glioblastoma: An Overview.Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and beta2-microglobulin downregulation in breast cancer.Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.Clinical relevance of human mammaglobin mRNA in pleural effusion from patients undergoing thoracoscopy: a pilot study.Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies.Amplification of MET in a Patient with Malignant Pleural Mesothelioma.FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma.CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumabHexaprimer amplification refractory mutation system PCR for simultaneous single-tube genotyping of 2 close polymorphismsAssociation of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosisDetection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patientsThe "in situ" expression of human leukocyte antigen class I antigens is not altered by cryopreservation in human arterial allograftsSoluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup studyImmunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanomaEpigenetic Targeting of GlioblastomaImmune Checkpoints and Innovative Therapies in GlioblastomaEarly replication of Friend leukaemia viruses in spleen macrophagesDetection of anti-idiotypic antibodies to HLA (anti-anti-HLA antibodies) by use of human monoclonal antibodiesHLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell linesTelomere length of donors influences granulocyte recovery in children after hematopoietic stem cell transplantationMET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization
P50
Q26784500-99547E50-07B7-48C3-ABC5-8459CABDA4C4Q33798642-E204CE78-880E-4F7F-B2BF-C06058F737DCQ34621749-952FF23D-1FF5-4904-9742-16E177AC8809Q36105814-F2DD0B09-EB17-4164-99B8-4CEDEC037822Q36139709-9B71325F-28FD-46C4-9373-BCB748A70936Q37687254-2E7A4310-F45B-414E-B483-7D45A923425EQ38897274-AD17DA03-4E32-43E8-95D8-F715C66D2CBCQ38997917-672B06C3-EB62-4E6E-9A62-F6479A9F768CQ39280197-EBCAE318-F400-4E3E-897F-F7ED2A82A175Q39748066-30CE3D94-E109-465C-A35E-762594B3E22AQ40226135-42FC2BAF-0C8E-4C72-97C9-596D971DBC2BQ40695159-29E9046A-4CE6-42D3-B16B-125B9557F5AAQ40776097-10E0AC29-7FBF-47F1-BEE5-781450E874B9Q43072159-5627A659-EE8C-4D33-9F9C-F26823175ADCQ43455435-25462A31-96E8-4BE5-B58D-5817EA6ECC43Q44534218-2D2D2E57-D28F-408D-8703-359933DDC4FCQ47142132-00C626AE-2509-4A7F-B477-F8C414737AE8Q47895518-B947C6FC-32BF-4CBF-B2F4-8951F260D425Q51563636-DFE498D7-94F7-4368-B552-367CB9DA0C5BQ52659362-6ECEB126-9E07-4E91-9DAC-D7CD9AC107F8Q53079690-5F73F2A2-0D22-423B-B9DC-0A04D00A97D9Q53165545-79DB9EA5-C1C1-4D20-876E-57984B0D1871Q53667526-2FE598FC-1637-40E5-B8B7-14BB71D27E9DQ53786777-4381EE7A-FD16-475E-87D3-92E02FAE24ABQ54244650-B11148E7-8541-4773-9658-BFB59F75CB0FQ54751754-1110DE20-692A-4B95-99CD-C373B6B74DF3Q56891361-5ED25729-C65D-4EEA-A11C-8694CC69D0B4Q56900891-C5228D8D-FECE-4B28-8874-93B158ED7063Q56901252-4426DB0C-7AF2-4B44-B362-C7B2AF1B79C7Q56904499-8F7604E6-A988-4BE4-BFE3-F733EAD4E14BQ56996194-B681FE43-8B84-4A79-A745-BD3C16493290Q57475128-C938EF35-E36A-49B8-BDC4-488DE0D9CB60Q57781473-6B2A5975-7960-4BD0-8AB7-BA4620EBDBCCQ58554073-A152C45C-EEB1-4C0E-9376-CD53B9DD0940Q58573409-2CB77610-CBA0-4EB4-8692-481B48A0DA2CQ61649294-009C0E10-155A-423D-9906-3B2F14C53A1BQ69494257-0AACFCF0-DC4D-476E-87D2-6A52B48AFC74Q81201456-56786074-BC4D-4F99-BABF-5607C5F0812EQ83380119-0AE44914-EC39-48F0-976A-AC3CBBAB0469Q87159094-19C7F896-E6B5-47C5-BCDB-9EE768813D61
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
M P Pistillo
@ast
M P Pistillo
@en
M P Pistillo
@es
M P Pistillo
@nl
type
label
M P Pistillo
@ast
M P Pistillo
@en
M P Pistillo
@es
M P Pistillo
@nl
prefLabel
M P Pistillo
@ast
M P Pistillo
@en
M P Pistillo
@es
M P Pistillo
@nl
P31
P496
0000-0002-1154-4121